Cancer Immunotherapy 人氣： 1792
2015年12月18日於新加坡舉辦的癌症免疫療法研討會，邀請各國知名專家學者共同參與，分享治療經驗並討論免疫療法的未來走向，針對癌症免疫療法目前FDA認可的適應症：黑色素瘤 (melanoma) 和非小細胞肺癌 (Non-small cell lung cancer) 治療，作更深入的探討和臨床經驗分享，會議演講內容將陸續免費分享在Elsevier全球醫藥新知-醫學持續教育-線上研討會
- Grant McArthur教授：澳洲皇家內科醫學院榮授院士 (Fellow, Royal Australasian College of Physicians)-演講連結
- 張文震醫師：台灣林口長庚醫院腫瘤科副教授級主治醫師 演講連結
- Dae Ho Lee醫師：韓國蔚山大學 & 峨山醫學中心副教授 (演講連結)
Immuno-Oncology: Investigation of Latest Trends on Cancer ImmunotherapyOn December 18, 2015, the meeting “Immuno-Oncology: Investigation of Latest Trends on Cancer Immunotherapy” was hosted at the Fairmont Singapore & Swissôtel The Stamford in Singapore, bringing together experts around the Asia-Pacific region to share and discuss their clinical experiences with the latest immuno-oncology (I-O) regimens for the treatment of cancer. Dr. Alex Y. Chang, Emeritus Medical Director of Johns Hopkins Singapore, served as the Moderator of the meeting. In his opening remarks, Dr. Chang declared that it was an exciting time now to be in the field of immuno-oncology, as new results are being published almost every hour. Furthermore, I-O medications such as nivolumab have shown encouraging activity against a very broad spectrum of disease, offering hope to patients with glioblastoma, non-small- cell lung cancer (NSCLC), and many other difficult-to- treat cancers. However, Dr. Chang also noted three main issues with I-O therapy that are yet to be resolved: First, the absence of precise biomarkers to predict disease and prognosis; Second, a lack of understanding as to why some patients do not respond to I-O therapy; and Third, a need to evaluate the cost-effectiveness of treatment, as high drug prices might well limit the availability of novel I-O medications. Dr. Chang was followed by lectures from Dr. Grant McArthur of Australia, Dr. John Wen-Cheng Chang of Taiwan, and Dr. Dae Ho Lee of South Korea, after which Dr. Han-Ting Hu of Taiwan presented several interesting cases. Attendees enthusiastically participated in the Q&A sessions and panel discussion, allowing for a robust and fruitful exchange of ideas regarding the clinical application of immunotherapy in oncology today.
Highlights• In opening remarks, Dr. Alex Y. Chang of Johns Hopkins Singapore referred to the new results of immune checkpoint inhibitors in melanoma, NSCLC, and other difficult-to- treat cancers, and outlined three major challenges facing I-O therapy today: First, the absence of predictive and prognostic biomarkers; Second, a lack of understanding regarding resistance mechanisms in poorly responding patients; and Third, a need to evaluate cost-effectiveness and prevent high drug prices from limiting the availability of novel I-O medications.
• Dr. Grant McArthur of the University of Melbourne, Australia, outlined the cancer immunity cycle in his lecture, and highlighted the enhanced efficacy and safety of current I-O medications such as anti-CTLA- 4 and anti-PD- 1 antibodies, which are non-redundant immune checkpoints in T cell. In future, these drugs may potentially be combined with target therapies for better anti-cancer effects.
• Dr. John Wen-Cheng Chang of Chang Gung Memorial Hospital-Linkou, Taiwan presented an overview of I-O therapies for NSCLC, and highlighted the importance of a uniform characterization and definition of PD-L1 expression in patients, as this would be useful for identifying potentially responsive patient populations.
• Dr. Dae Ho Lee of the University of Ulsan, South Korea, stressed the need for clinicians to be fully aware of the toxicities associated with each type of I-O therapy, including combination regimens, and noted that toxicity can vary between different I-O agents, treatment schedules, and tumor types.
• Dr. Han-Ting Hu of the Koo Foundation Sun-Yat- Sen Cancer Center, Taiwan presented two cases of metastatic melanoma; one case responded well to ipilimumab + nivolumab combination therapy followed by nivolumab monotherapy, while the other case showed a mixed response to nivolumab therapy. Dr. Hu also highlighted the issues of high drug cost and few options following treatment failure for I-O therapy.